12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Taliglucerase alfa regulatory update

Protalix said FDA accepted the company's response to a February complete response letter for Gaucher's disease candidate taliglucerase alfa. FDA designated the response a...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >